Chen Robert T, Shimabukuro Tom T, Martin David B, Zuber Patrick L F, Weibel Daniel M, Sturkenboom Miriam
Office of Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Office of Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Vaccine. 2015 Nov 27;33 Suppl 4(0 4):D46-54. doi: 10.1016/j.vaccine.2015.06.073. Epub 2015 Oct 1.
Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with near elimination of target vaccine-preventable diseases that result in relative greater prominence of adverse events following immunizations, both true reactions and temporally coincidental events. There are several ways in which vaccine safety capacity can be improved to potentially mitigate the impact of future vaccine safety controversies. This paper aims to take a "lifecycle" approach, examining some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed (specifically U.S. and Europe) and low- and middle-income countries.
从20世纪最后几十年开始，几个国家出现了重大的疫苗安全争议。随着更多国家的免疫规划成熟，目标疫苗可预防疾病几乎被消除，这导致免疫接种后不良事件（包括真正的反应和时间上巧合的事件）相对更加突出，这种周期性的疫苗安全争议在不久的将来不太可能消失。有几种方法可以提高疫苗安全能力，以潜在地减轻未来疫苗安全争议的影响。本文旨在采用“生命周期”方法，研究在发达国家（特别是美国和欧洲）以及低收入和中等收入国家，在疫苗上市前和上市后提高疫苗安全性的一些潜在机会。
